Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $12.19 in the prior trading day, Integra Lifesciences Holdings Corp (NASDAQ: IART) closed at $11.9, down -2.38%. In other words, the price has decreased by -$2.38 from its previous closing price. On the day, 0.91 million shares were traded. IART stock price reached its highest trading level at $12.07 during the session, while it also had its lowest trading level at $11.74.
Ratios:
Our goal is to gain a better understanding of IART by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.80 and its Current Ratio is at 3.14. In the meantime, Its Debt-to-Equity ratio is 1.93 whereas as Long-Term Debt/Eq ratio is at 1.88.
On December 02, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 05 ’25 when GRAVES JEFFREY A bought 9,000 shares for $11.35 per share. The transaction valued at 102,150 led to the insider holds 41,086 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IART now has a Market Capitalization of 927138368 and an Enterprise Value of 2666761216. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.56 while its Price-to-Book (P/B) ratio in mrq is 0.89. Its current Enterprise Value per Revenue stands at 1.623 whereas that against EBITDA is 8.364.
Stock Price History:
The Beta on a monthly basis for IART is 1.04, which has changed by -0.54872966 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, IART has reached a high of $27.13, while it has fallen to a 52-week low of $10.87. The 50-Day Moving Average of the stock is -6.22%, while the 200-Day Moving Average is calculated to be -12.34%.
Shares Statistics:
The stock has traded on average 918.43K shares per day over the past 3-months and 625450 shares per day over the last 10 days, according to various share statistics. A total of 77.83M shares are outstanding, with a floating share count of 65.88M. Insiders hold about 15.42% of the company’s shares, while institutions hold 93.57% stake in the company. Shares short for IART as of 1767139200 were 7369471 with a Short Ratio of 8.02, compared to 1764288000 on 6653021. Therefore, it implies a Short% of Shares Outstanding of 7369471 and a Short% of Float of 15.39.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 9.0 analysts currently analyzing and rating the stock of Integra Lifesciences Holdings Corp (IART).The consensus estimate for the next quarter is $0.48, with high estimates of $0.54 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.22 and $2.17 for the fiscal current year, implying an average EPS of $2.2. EPS for the following year is $2.35, with 11.0 analysts recommending between $2.55 and $2.27.
Revenue Estimates
9 analysts predict $429.62M in revenue. The current quarter. It ranges from a high estimate of $434.5M to a low estimate of $426M. The current estimate, Integra Lifesciences Holdings Corp’s year-ago sales were $442.64MFor the next quarter, 9 analysts are estimating revenue of $392.15M. There is a high estimate of $398.4M for the next quarter, whereas the lowest estimate is $382.01M.
A total of 10 analysts have provided revenue estimates for IART’s current fiscal year. The highest revenue estimate was $1.63B, while the lowest revenue estimate was $1.63B, resulting in an average revenue estimate of $1.63B. In the same quarter a year ago, actual revenue was $1.61BBased on 10 analysts’ estimates, the company’s revenue will be $1.68B in the next fiscal year. The high estimate is $1.7B and the low estimate is $1.65B.
